Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation (vol 8, pg 525, 2019)

首页> 外文期刊>Progress in Artificial Intelligence >Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation (vol 8, pg 525, 2019)

【24h】

Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation (vol 8, pg 525, 2019)

机译：EGFR +非小细胞肺癌患者患者Osimertinib治疗的临床疗效分析（Vol 8，PG 525,2019）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Progress in Artificial Intelligence》 |2020年第1期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类计算技术、计算机技术;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation (vol 8, pg 525, 2019) [J] . Progress in Artificial Intelligence . 2020,第1期

机译：EGFR +非小细胞肺癌患者患者Osimertinib治疗的临床疗效分析（Vol 8，PG 525,2019）
2. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients [J] . Qiufan Zheng, Shaodong Hong, Yan Huang, Clinical and Translational Medicine . 2020,第6期

机译：EGFR T790M相对突变纯度预测非小细胞肺癌患者的Osimertinib治疗疗效
3. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients [J] . Progress in Artificial Intelligence . 2020,第1期

机译：EGFR T790M相对突变纯度预测非小细胞肺癌患者的Osimertinib治疗疗效
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Crippling Rapid Evolution of Metastasis and Drug Resistance in A549 Non-Small Cell Lung Cancer Cells with the Clinically Relevant HSP90 Inhibitor AUY922 [D] . Bacon, Nickolas. 2021

机译：临床相关的HSP90抑制剂Auy922，A549非小细胞肺癌细胞转移和耐药性快速演变和耐药性的快速演变
6. Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation [O] . Chong-Kin Liam, Mau-Ern Poh, Yong-Sheng Liam 2019

机译：对T790M突变引起的酪氨酸激酶抑制剂获得性耐药的表皮生长因子受体突变型非小细胞肺癌患者临床特征对奥西替尼治疗疗效的影响
7. The Real-Life Efficacy And Safety of Osimertinib In Pretreated Advanced Non-Small Cell Lung Cancer Patients With T790M Mutation: A Turkish Oncology Group Study [O] . Mutlu Hizal, Burak Bilgin, Nail Paksoy, 2021

机译：Osimertinib在预处理晚期非小细胞肺癌患者T790M突变的真实效果和安全性：土耳其肿瘤学群体研究

Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation (vol 8, pg 525, 2019)

著录项

相似文献

相关主题

期刊订阅